Patents Issued in October 6, 2020
  • Patent number: 10793830
    Abstract: Provided is a method of inducing the differentiation of a stem cell into nerve progenitor cells, comprising the step (1) of forming a homogenous aggregate of stem cells in a serum-free medium (1) and the step (2) of suspension-culturing the homogenous aggregate of stem cells in the presence of a basement membrane reference standard.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: October 6, 2020
    Assignee: RIKEN
    Inventors: Yoshiki Sasai, Mototsugu Eiraku
  • Patent number: 10793831
    Abstract: The present invention provides methods, kits, and compositions for reducing an innate immune system response in a human or animal cell, tissue or organism. One embodiment comprises: introducing an Agent mRNA comprising in vitro-synthesized mRNA encoding one or more proteins that affect the induction, activity or response of an innate immune response pathway; whereby, the innate immune response in the cell, tissue or organism is reduced compared to the innate immune response in the absence of the Agent mRNA. Other embodiments are methods, compositions and kits for using an Agent mRNA for treating a disease or medical condition in a human or animal that exhibits symptoms of an elevated innate immune system, or for reducing an innate immune response that is induced in a human or animal cell, tissue or organism by a Foreign Substance that is administered to the cell, tissue or organism.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 6, 2020
    Assignee: CELLSCRIPT, LLC
    Inventors: Cynthia Chin, Anthony D. Person, Gary A. Dahl
  • Patent number: 10793832
    Abstract: A method for producing pancreatic endocrine cells, the method including introducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: October 6, 2020
    Assignee: Juntendo Educational Foundation
    Inventors: Masahito Matsumoto, Yasushi Okazaki, Izumi Sugahara
  • Patent number: 10793833
    Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and use thereof.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: October 6, 2020
    Assignee: The Regents of the University of California
    Inventors: Steven F. Dowdy, Naohisa Yoshioka
  • Patent number: 10793834
    Abstract: Presented herein are live-attenuated viruses and methods of generating thereof from a parental virus through a plurality of nucleotide substitutions in the viral genome. The nucleotide substitutions result in a change in codon usage bias within codons of one or more protein encoding sequences and no change in amino acid sequences of the proteins. The live-attenuated viruses display unaltered replication in avian hosts for propagation, but attenuated replication in mammalian hosts, when compared to the replication of the parental virus. The live-attenuated viruses in a form of improved vaccines can be used to elicit protective immune responses.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 6, 2020
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Lit Man Poon, Lok Yan Fan
  • Patent number: 10793835
    Abstract: The invention provides an isolated chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated viral (AAV) genome, an isolated rBoV comprising human bocavirus capsid protein and a recombinant BoV genome, and uses therefor. For example, the chimeric virus may be employed to deliver transgenes, such as those encoding therapeutic or prophylactic gene products, to mammalian cells.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: October 6, 2020
    Assignees: University of Iowa Research Foundation, University of Kansas
    Inventors: Ziying Yan, John F. Engelhardt, Jianming Qiu
  • Patent number: 10793836
    Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: October 6, 2020
    Assignee: Codexis, Inc.
    Inventors: Oscar Alvizo, Melissa Ann Mayo, Jeffrey C. Moore
  • Patent number: 10793837
    Abstract: This disclosure concerns a novel modular docosahexaenoic acid (DHA) synthase and recombinant host organisms genetically modified with such synthase and one or more accessory proteins that allow for and/or improve the production of PUFAs in the host organism. The disclosure also concerns methods of making and using such organisms as well as products obtained from such organisms.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 6, 2020
    Assignee: DSM IP Assets B.V
    Inventors: James G. Metz, Jun Wang, Bastien Chevreux, Ross E. Zirkle, Anne-Cecile Bayne, James Casey Lippmeier
  • Patent number: 10793838
    Abstract: Compositions are disclosed herein comprising poly alpha-1,3-1,6-glucan with a weight average degree of polymerization (DPw) of at least 1000. This glucan polymer comprises at least 30% alpha-1,3 linkages and at least 30% alpha-1,6 linkages. Further disclosed are glucosyltransferase enzymes that synthesize poly alpha-1,3-1,6-glucan. Ether derivatives of poly alpha-1,3-1,6-glucan and methods of using such derivatives as viscosity modifiers are also disclosed.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: October 6, 2020
    Assignee: DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
    Inventors: Jayme L. Paullin, Mark S. Payne, T. Joseph Dennes, Yefim Brun, Rakesh Nambiar, Thomas H. Scholz
  • Patent number: 10793839
    Abstract: The present invention relates to cell lines that are genetically modified to overexpress a ?-galactoside ?-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: October 6, 2020
    Assignee: Cevec Pharmaceuticals GmbH
    Inventors: Silke Wissing, Jens Wölfel, Nicole Faust
  • Patent number: 10793840
    Abstract: Methods to create two component signal transduction systems by replace the DNA binding domains and output promoters in bacteria are described.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 6, 2020
    Assignee: William Marsh Rice University
    Inventors: Jeffrey J. Tabor, Sebastian Schmidl, Ravi Sheth, Felix Ekness, Brian Landry, Nikola Dyuglyarov
  • Patent number: 10793841
    Abstract: The present invention provides engineered T7 RNA polymerase variants and compositions thereof. These variants have been evolved for selective incorporation of the symmetrical capped GTP analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for using the variants provided herein. The present invention further provides for the use of the compositions provided herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Codexis, Inc.
    Inventors: Mathew G. Miller, Chinping Chng, Oscar Alvizo, Melissa Ann Mayo, James Nicholas Riggins, Xiang Yi, Jonathan S. Penfield, Gjalt W. Huisman
  • Patent number: 10793842
    Abstract: The present disclosure provides variant Cas9 proteins, nucleic acids encoding the variant Cas9 proteins, and host cells comprising the nucleic acids. The present disclosure provides systems that include a subject variant Cas9 protein (and/or a nucleic acid encoding the variant Cas9 protein) and a Cas9 guide RNA. In some cases, a subject system includes a PAMmer and/or a donor polynucleotide. The variant Cas9 proteins and the nucleic acids encoding the variant Cas9 proteins are useful in a wide variety of methods, which are also provided. In some embodiments, a variant Cas9 protein includes a RuvC domain, an HNH domain, and a disrupted RuvC/HNH linker region that reduces the RuvC cleavage activity of the protein. In some embodiments, a variant Cas9 protein includes a deletion (of all or a part of the HNH domain) or an insertion (within the HNH domain) that reduces the HNH cleavage activity of the protein.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: October 6, 2020
    Assignee: the regents of the university of california
    Inventors: Samuel H. Sternberg, Jennifer A. Doudna
  • Patent number: 10793843
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: October 6, 2020
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • Patent number: 10793844
    Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used as amylases to catalyze the hydrolysis of starch into sugars.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: October 6, 2020
    Assignee: BASF Enzymes LLC
    Inventors: Kevin A. Gray, Nahla M. Aboushadi, James B. Garrett
  • Patent number: 10793845
    Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: October 6, 2020
    Assignees: Novozymes A/S, Novozymes, Inc.
    Inventors: Nikolaj Spodsberg, Tarana Shaghasi, Matt Sweeney, Feng Xu, Kirk Schnorr
  • Patent number: 10793846
    Abstract: Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO: 1, are provided, wherein (a) the polypeptide degrades a PFQPQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: October 6, 2020
    Assignees: University of Washington, The Regents of the University of California
    Inventors: Ingrid Swanson Pultz, Clancey Wolf, Justin Bloomfield Siegel, Christine Elaine Tinberg, Lance Stewart, David Baker
  • Patent number: 10793847
    Abstract: The present invention provides a method, wherein the method forms a biofilm, wherein the biofilm comprises a population of at least one bacterial strain attached to particles, wherein the biofilm is configured to colonize a gut of a subject in need thereof for at least five days, when ingested by the subject, the method comprising: a. obtaining a population comprising at least one strain of bacteria; b. inoculating a growth medium containing particles with the population comprising at least one strain of bacteria; c. incubating the particles with the population comprising at least one bacterial strain for a time sufficient for the population of at least one strain of bacteria to attach to the particles; and d. culturing the population comprising at least one strain of bacteria attached to the particles in a growth medium, for a time sufficient to form a biofilm.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 6, 2020
    Assignee: MYBIOTICS PHARMA LTD.
    Inventors: David Baram, Rachel Diamant, David Daboush
  • Patent number: 10793848
    Abstract: The invention relates to an immobilized protein material comprising a protein that is immobilized on a glass material or organic polymer through affinity tag binding. The glass material may be a porous glass material such as (hybrid) controlled porosity glass. The invention also relates to the use of an immobilized enzyme material as a heterogeneous biocatalyst in chemical synthesis. The invention further relates to a method for the immobilization of affinity tagged proteins on a glass material or organic polymer, and to a method for the purification and isolation of affinity tagged proteins by the immobilization of such proteins on a glass material or organic polymer.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 6, 2020
    Assignee: ENGINZYME AB
    Inventors: Karim Engelmark Cassimjee, Jan-Erling Bäckvall
  • Patent number: 10793849
    Abstract: A microfluidic device is disclosed having an enclosed chamber containing a filter for purifying biological or chemical analytes from a complex biological sample, said chamber housing a plurality of ports in addition to said filter, as follows: a first port enabling gas communication of the chamber with a vacuum generator, via a first flow path; a second port enabling liquid communication of the chamber with one or more reservoirs, via a second flow path; a third port enabling gas and liquid communication of the chamber with both one or more receiving containers and a vacuum generator, via a third flow path; and a filter located between the third port and both the first and second port, so that a fluid entering the chamber through the first and/or second port and exiting the chamber through the third port flows through the filter. The invention also relates to a method using the microfluidic device.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: October 6, 2020
    Assignee: STAT-DIAGNOSTICA & INNOVATION S.L.
    Inventors: Francesc Benitez Porras, Josep Pareja Gómez
  • Patent number: 10793850
    Abstract: The present invention relates to a method for carrying out recombination at a target locus.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: October 6, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Nathalie Wiessenhaan, Catharina Petronella Antonia Maria Kolen, Bernard Meijrink, Viktor Marius Boer, Johannes Andries Roubos, Yvonne Johannes Odilia Arendsen
  • Patent number: 10793851
    Abstract: Compositions and methods for tracking combinations of mutations in populations by coupling DNA assembly and paired-end sequencing technology with high-throughput sequencing. This allows for an unlimited number of mutation sites in a population of microorganisms to be identified, and allows sites to be sequenced across several replicates. Unique identifiers (DNA barcodes) can be used to measure fitness data by sequencing of the barcodes multiplexed with the mutation sites with high-throughput short sequencing read technology, allowing selections to be rapidly performed on populations of known combinatorial genotypes.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 6, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Ryan T. Gill, Ramsey Zeitoun
  • Patent number: 10793852
    Abstract: A data storage medium is disclosed comprising a dried product formed by drying a salt solution dried together with artificially synthesized DNA molecules encoding digital information. The cation in the salt may be calcium, magnesium, lanthanum, or another cation. The anion in the salt may be chloride, phosphate, or another anion. The DNA is protected from degradation by drying with the salt. Stored DNA may be freed from the salt for sequencing or other analysis by mixing the dried product with a chelator. The dry product formed from DNA and a salt may contain more than 30% DNA by weight and degrade at rates that are less than a third of rate at which untreated DNA degrades.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 6, 2020
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Karin Strauss, Weida Chen, Robert Grass, Alexander Xavier Christof Kohll, Bichlien Hoang Nguyen
  • Patent number: 10793853
    Abstract: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: October 6, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 10793854
    Abstract: Provided are a gene involved in the regulation of the amount of melanin in keratinocytes, and the control of the color of skin or hair, the gene being selected from the group consisting of ATG7 gene, RAB11A gene, CLIP-170 gene, Rubicon gene and RAB7B gene, and a molecule encoded by the gene.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 6, 2020
    Assignee: Kao Corporation
    Inventors: Daiki Murase, Akira Hachiya
  • Patent number: 10793855
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: October 6, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Patent number: 10793856
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 6, 2020
    Assignee: Biogen MA Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 10793857
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sodium channel, voltage-gated, alpha subunit (SCNA), in particular, by targeting natural antisense polynucleotides of Sodium channel, voltage-gated, alpha subunit (SCNA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SCNA.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: October 6, 2020
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Belinda De Leon, Carlos Coito, Jane H. Hsiao
  • Patent number: 10793858
    Abstract: Ribozymes exhibiting tRNA synthetase activity and substrate specificity, as well as methods for engineering and producing the same, are disclosed. The ribozymes of the present disclosure comprise a T-box module fused with a flexizyme module. The flexizyme module provides high promiscuity with respect to amino acid substrates and the T-box module provides tRNA substrate specificity, which may be engineered as desired. Systems are also described for aminoacylation of suppressor tRNAs with unnatural amino acids (uAAs), such systems comprising the ribozyme previously mentioned, suppressor tRNA, and the desired uAA(s). Methods for incorporating a uAA into a growing polypeptide chain using the ribozyme hereof are also provided.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 6, 2020
    Assignees: Purdue Research Foundation, The Regents of the University of California
    Inventors: Barbara L. Golden, Ji Chen, Andrej Luptak, Rui Gan
  • Patent number: 10793859
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
  • Patent number: 10793860
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of HBV gene expression and/or activity, and/or modulate a HBV gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against HBV gene expression.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: October 6, 2020
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Steven Bartz, Duncan Brown, Michael Robinson
  • Patent number: 10793861
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 6, 2020
    Assignees: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
  • Patent number: 10793862
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: October 6, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 10793863
    Abstract: The present disclosure describes genes and proteins of the coenzyme F430 synthetic pathway. The genes and proteins in the pathway find uses as isolated nucleic acids, transformation vectors, a transformation media, genetically modified cells, methods of modulating methanogenesis, methods of modulating methane oxidation, methods of making a tetrapyrrole compound, methods of oxidizing methane, methods of biogenic methane synthesis is provided, methods of assaying an organism for potential methanogenic or methanotrophic activity, and isolated proteins.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 6, 2020
    Assignee: AUBURN UNIVERSITY
    Inventor: Steven Mansoorabadi
  • Patent number: 10793864
    Abstract: In one aspect, the invention relates to methods and compositions for determining migration of a virus particle to the nucleus of a cell. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 6, 2020
    Assignee: GEORGE MASON UNIVERSITY
    Inventors: Mark Spear, Yuntao Wu
  • Patent number: 10793865
    Abstract: A prokaryotic protein appearing to have a Bin/Amphiphysin/Rvs (BAR) domain, previously known in eukaryotes, has been identified. Expression of this protein causes formation of outer membrane extensions.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 6, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Daniel A. Phillips, Sarah M. Glaven
  • Patent number: 10793866
    Abstract: In the invention described here, the approach is to formulate an edible vaccine based on N-terminal yeast surface display expression platform that producing S.cerevisiae EBY100/pYD5-preS2/S(adw) and S.cerevisiae EBY100/pYD5-preS2/S(adr) for protecting and treating human against hepatitis B virus (HBV) infection, suggesting that yeast surface display expression system expressing HBsAg antigen has potential as a prophylactic treatment for HBV in human via oral vaccination. The technology developed in this patent application can also be used to produce edible (oral) vaccines for preventing and treating other infectious diseases in human.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: October 6, 2020
    Assignee: DrD LifeSciences Group Limited
    Inventors: Dominic Man-Kit Lam, Olivia Yee-Yee Lam, Han Lei
  • Patent number: 10793867
    Abstract: The invention relates to biotechnology and provides novel methods for sequence-specific or sequence-directed transcription activator-like effector recombinase-mediated integration of DNA sequences of interest into host genomes. The invention also provides methods of use for novel plant transformation vectors and expression cassettes, which include novel combinations of chimeric recombinases with plant expression and transformation elements. Methods for gene-targeting, DNA sequence removal, genome modification, and molecular breeding are also provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 6, 2020
    Assignee: Monsanto Technology, LLC
    Inventors: Jonathan C. Lamb, Richard J. Lawrence
  • Patent number: 10793868
    Abstract: The invention relates to genetically modified plants with an altered seed phenotype, in particular increased seed size. The invention relates to a plant that does not produce a functional NGAL2 polypeptide or functional NGAL2 and NGAL3 polypeptides. NGAL2 and NGAL3 are members of the RAV family and comprise a B3 DNA-binding domain and a transcriptional repression motif.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: October 6, 2020
    Assignee: INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY CHINESE ACADEMY OF SCIENCES
    Inventor: Yunhai Li
  • Patent number: 10793869
    Abstract: The present invention provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 6, 2020
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: Edwards M. Allen, Larry A Gilbertson, Sara E. Heisel, Shihshieh Huang, Elysia K. Krieger, Thomas M. Malvar
  • Patent number: 10793870
    Abstract: Provided are methods of increasing yield, biomass, growth rate, vigor, and/or abiotic stress tolerance of a plant by expressing within the plant an exogenous polynucleotide comprising a nucleic acid sequence at least 80% identical to SEQ ID NO: 84 or 921; or an exogenous polynucleotide encoding a polypeptide at least 80% identical to SEQ ID NO: 188.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: October 6, 2020
    Assignee: Evogene Ltd.
    Inventors: Eyal Emmanuel, Zur Granevitze, Alex Diber, Basia Judith Vinocur, Sharon Ayal, Yoav Herschkovitz
  • Patent number: 10793871
    Abstract: Provided are a nucleic acid molecule encoding a Gle1 protein variant comprising a phytic acid-binding pocket, a protein encoded by the nucleic acid molecule and a method using the nucleic acid molecule. The Gle1 protein variant has an increased sensitivity to phytic acid in plants, and also has an effect of highly increasing vegetative growth, seed yield, seed performance and abiotic stress tolerance in plants containing a low level of phytic acid. Therefore, high yield low-InsP6 crops may be cultivated using the nucleic acid molecule.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 6, 2020
    Assignee: UNIVERSITY-INDUSTRY FOUNDATION, YONSEI UNIVERSITY
    Inventors: Hyun Sook Pai, Ho-Seok Lee
  • Patent number: 10793872
    Abstract: Compositions and methods for conferring herbicide tolerance to bacteria, plants, plant cells, tissues and seeds are provided. Compositions include polynucleotides encoding herbicide tolerance polypeptides, vectors comprising those polynucleotides, and host cells comprising the vectors. The nucleotide sequences of the invention can be used in DNA constructs or expression cassettes for transformation and expression in organisms, including microorganisms and plants. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated polynucleotides encoding HPPD inhibitor tolerance polypeptides are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: October 6, 2020
    Assignee: BASF Agricultural Solutions Seed US LLC
    Inventors: Fabien Poree, Volker Heinrichs, Gudrun Lange, Bernd Laber, Cheryl Peters, Laura Schouten
  • Patent number: 10793873
    Abstract: The invention provides cells and animals, as well as methods of producing cells and animals, that express at least one interfering RNA molecule to regulate the expression of a specific gene or family of genes. The invention further provides novel iRNA molecules, as well as DNA templates for producing iRNA molecules.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: October 6, 2020
    Assignee: Revivicor, Inc.
    Inventor: Kevin Wells
  • Patent number: 10793874
    Abstract: Methods and compositions are provided for generating targeted genetic modifications on the Y chromosome or a challenging target locus. Compositions include an in vitro culture comprising an XY pluripotent and/or totipotent animal cell (i.e., XY ES cells or XY iPS cells) having a modification that decreases the level and/or activity of an Sry protein; and, culturing these cells in a medium that promotes development of XY F0 fertile females. Such compositions find use in various methods for making a fertile female XY non-human mammal in an F0 generation.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 6, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Gustavo Droguett, Anthony Gagliardi, Junko Kuno, Wojtek Auerbach, David Valenzuela
  • Patent number: 10793875
    Abstract: Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: October 6, 2020
    Assignee: Nant Holdings IP, LLC
    Inventors: Patrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi
  • Patent number: 10793876
    Abstract: The present disclosure relates to the design of a retro- or lenti-viral HBV (hepatitis B virus) hybrid vector for delivery of HBV genomes into cells such as liver cells. Provided herein are design, methodology, compositions, and the like for such vectors for delivering HBV genes or genomes into cells for anti-HBV drug screening, HBV research, or test of anti-HBV therapeutics.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 6, 2020
    Assignee: VIRONGY L.L.C.
    Inventor: Yuntao Wu
  • Patent number: 10793877
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 6, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIEQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • Patent number: 10793878
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 6, 2020
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10793879
    Abstract: Methods and systems for isolating a high purity starch stream are provided. The methods provide an initial treatment step in advance of traditional grinding or fractionation operations (such as dry milling or wet milling operations) that facilitate separation of starch from other components of starch-based grains, for example facilitate separation of soft endosperm from other components of corn kernels including hard endosperm. The systems include a first treatment system for separating a high purity starch stream from other components of the grain stream, wherein the system can be configured as a bolt on for traditional milling operations such as wet milling and dry milling operations.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: October 6, 2020
    Assignee: POET Research, Inc.
    Inventors: Steven Redford, Todd Peterson